טוען...
Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
AIMS: Sacubitril/valsartan (SV) reduced heart failure hospitalization and cardiovascular mortality compared with enalapril in the Prospective Comparison of ARNI with ACE‐I to Determine Impact on Global Mortality and Morbidity in Heart Failure trial. However, this trial excluded patients with end sta...
שמור ב:
| הוצא לאור ב: | ESC Heart Fail |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7261577/ https://ncbi.nlm.nih.gov/pubmed/32153122 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12659 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|